Attempts to obtain neuroprotection in Parkinson's disease

Neurology

Volumn 49, Issue 1 SUPPL., 1997, Pages

  Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROPROTECTIVE AGENT; SELEGILINE;

ARTICLE; DOPAMINE METABOLISM; DRUG EFFECT; DRUG SCREENING; HUMAN; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0030741788     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.49.1_suppl_1.s26     Document Type: Article

References (87)

1. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. Carnforth, UK: Parthenon Publishing Group, 1992:89-112.
2. Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990; 40(Suppl 3):17-30.
3. Golbe LI. The genetics of Parkinson's disease: a reconsideration. Neurology 1990;40(Suppl 3):7-14.
4. Jenner P, Olanow CW. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:24-45.
5. Jenner P, Schapira AH, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
6. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993;16:439-444.
7. Hall B, Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci 1985;8:22-29.
8. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(Suppl 3):32-37.
9. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1997, in press.
10. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
11. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
12. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992; 593:343-346.
13. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an x-ray microanalysis. J Neurochem 1991;56:446-451.
14. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65:717-724.
15. Gutteridge JM, Quinlan GJ, Clark I, Halliwell B. Aluminum salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta 1985;835:441-447.
16. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982-33:305-310.
17. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
18. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
19. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
20. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827.
21. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989;163:1450-1455.
22. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on a-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994;35: 204-210.
23. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
24. Mytilineou C, Werner P, Molinari S, Di Rocco A, Cohen G, Yahr MD. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neural Transm 1994;8:223-228.
25. Ingold KU, Webb AC, Witter D, Burton GW, Metcalfe TA, Muller DP. Vitamin E remains the major lipid-soluble, chain-breaking antioxidant in human plasma even in individuals suffering severe vitamin E deficiency. Arch Biochem Biophys 1987;259:224-225.
26. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989;26:689-690.
27. Cohen G, Pasik P, Cohen B, Leist A, Mytinlineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1984;106:209-210.
28. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 1984;120:574-578.
29. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
30. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.
31. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
32. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
33. Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pans S, Bodian CA. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Arch Neurol 1989;46: 1275-1279.
34. Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995;37:95-98.
35. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307-469-472.
36. Parkinson's Disease Research Group in the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1606.
37. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996;40:841-845.
38. Tatton WG, Ju WY, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youim MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:202-220.
39. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672.
40. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion. J Neurochem 1985;45:1951-1953.
41. + in vivo. Eur J Pharmacol 1993; 243:241-247.
42. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M. Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
43. Tatton WG, Charmers-Redman ME. Modulation of gene expression rather than monoamine oxidase inhibition: L-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47(Suppl 3):S171-S183.
44. Carrillo MC, Kanai S, Nokubo M, Kitani K. L-deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1991;48:517-521.
45. Clow A, Hussain T, Glover V, Sandler M, Dexter DT, Walker M. L-deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm Gen Sect 1991;86:77-80.
46. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity. J Neurochem 1997;68:33-39.
47. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of L-(-)-desmethyl selegiline protects dopamine neurons from excitotoxicity in vitro. J Neurochem 1997;68:434-436.
48. Anglade P, Michel P, Marquez J, et al. Apoptotic degeneration of nigral dopaminergic neurons in Parkinson's disease. Proc Soc Neurosci 1995;21:489-493.
49. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992;19: 108-112.
50. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 1989;86:1398-1400.
51. Spencer JPE, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 1995;6:1480-1484.
52. +. Free Radie Biol Med 1992;13:581-583.
53. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurosci 1991;101:198-203.
54. Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons: a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994;170:136-140.
55. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435.
56. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals: possible participation of levodopa. Adv Neurol 1993;60:242-250.
57. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-507.
58. Spencer Smith T, Parker WD Jr, Bennett JP Jr. L-Dopa increases nigral production of hydroxyl radicals in vivo: potential L-Dopa toxicity? Neuroreport 1994;5:1009-1011.
59. Spencer JP, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-Dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353: 246-250.
60. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723.
61. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by dopa and iron. Neurosci Lett 1992;140:42-46.
62. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-Dopa on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478.
63. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-Dopa: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
64. Steece-Collier K, Collier TJ, Sladek CD, Sladek JR Jr. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-208.
65. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
66. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with PD: a five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
67. Olanow CW, Fahn S, Muenter M, et al. A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9: 40-47.
68. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5 year follow-up. Neurology 1987;37:826-828.
69. Olanow CW, Alberts M, Stajich J, Burch G. A randomized blinded study of low dose bromocriptine versus low dose carbidopa/levodopa in untreated Parkinson patients. In: Fahn S, Marsden D, Calne M, Goldstein M, eds. Recent developments in Parkinson's disease, vol. II. New York: Macmillan Health Care, 1987:201-208.
70. Carter AJ, Muller RE. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
71. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995; 18:34-42.
72. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res 1994;657:207-213.
73. Carvey PM, Ling ZD. The effects of pramipexole on mesencephalic-derived neurotrophic activity. Neurology 1997, in press.
74. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 1992;13:339-351.
75. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.
76. Clow A, Freestone C, Lewis E, Dexter D, Sandler M, Glover V. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 1993;164:41-43.
77. Hefti F, Melamed E, Bhawan J, Wurtman R. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
78. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990-993.
79. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of substantia nigra neurons and locus coeruleus in a patient receiving levodopa (2 gm) plus decarboxylase inhibitor over a four year period. Mov Disord 1986;1:65-68.
80. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
81. Ogawa N, Asanuma M, Kondo Y, Kawada Y, Yamamoto M, Mori A. Differential effects of chronic L-Dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 1994;171: 55-58.
82. Han S-K, Mytilineou C, Cohen G. L-Dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.
83. Kokotos Leonardi ET, Cheng B, Radcliffe PR, Olanow CW, Cohen G, Mytilineou C. L-dopa and L-deprenyl protect against L-BSO induced cell death in cultured mesencephalic neurons. Soc Neurosci Abs 1997, in press.
84. Pardo B, Mena MA, Fahn S, Garcia de Yebenes J. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284.
85. 3H]spiperone binding. Brain Res 1986;379:294-299.
86. Pearce RKB, Banerji T, Jenner P, Marsden CD. Effects of repeated treatment with L-Dopa, bromocriptine and ropinorole in drug naive MPTP-treated common marmosets. Br J Pharmacol 1996;118(Suppl):37P.
87. Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado study discontinued. Eur J Clin Pharmacol 1992;43:357-363.